Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.56 |
| ▸ | BRS3 | P32247 | 6/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626827 | 0.78 | AOC3 (0.62) | AOC3CAPN1BRS3TAAR1HRH3 | |
| SCHEMBL19077883 | 0.77 | CAPN1 (0.63) | AOC3CAPN1BRS3TAAR1HRH3 | |
| SCHEMBL7688678 | 0.75 | HPGDS (0.50) | AOC3CAPN1BRS3TAAR1HTR1B | |
| SCHEMBL11552467 | 0.75 | HPGDS (0.50) | AOC3CAPN1BRS3TAAR1HRH3 | |
| SCHEMBL20900314 | 0.75 | AOC3 (0.58) | AOC3CAPN1BRS3TAAR1HRH3 | |
| SCHEMBL20900312 | 0.75 | AOC3 (0.58) | AOC3CAPN1BRS3TAAR1HRH3 | |
| SCHEMBL10565813 | 0.74 | AOC3 (0.62) | AOC3CAPN1BRS3TAAR1HRH3 | |
| SCHEMBL12598581 | 0.74 | AOC3 (1.00) | AOC3CAPN1BRS3TAAR1HRH3 | |
| SCHEMBL8957090 | 0.74 | HRH1 (0.62) | AOC3CAPN1BRS3TAAR1HTR1B | |
| SCHEMBL12877777 | 0.73 | GAA (0.47) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | AOC3 2890/4885CAPN1 4099/4885BRS3 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.